Gene therapy has been proposed as one therapeutic option in the search for suitable treatments for severe heart diseases. . However, the largest study using this type of therapy in patients with severe heart failure has been discontinued for failing to show positive results, according to an announcement made last April by Celladon, the pharmaceutical company that sponsored the trial. Nevertheless, experts believe that lessons learned from this clinical trial will serve to propose others. Promoting medically and ethically acceptable therapies is unquestionably a very necessary clinical objective (Nature Biotechnology 33; 573-74,2015).
La entrada Gene therapy for severe heart disease. Trials suspended aparece primero en Observatorio de Bioética, UCV.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.